Nuclear factor-kappaB activation by reactive oxygen species mediates voltage-gated K+ current enhancement by neurotoxic beta-amyloid peptides in nerve growth factor-differentiated PC-12 cells and hippocampal neurones

J Neurochem. 2005 Aug;94(3):572-86. doi: 10.1111/j.1471-4159.2005.03075.x. Epub 2005 Jun 22.

Abstract

Increased activity of plasma membrane K+ channels, leading to decreased cytoplasmic K+ concentrations, occurs during neuronal cell death. In the present study, we showed that the neurotoxic beta-amyloid peptide Abeta(25-35) caused a dose-dependent (0.1-10 microm) and time-dependent (> 12 h) enhancement of both inactivating and non-inactivating components of voltage-dependent K+ (VGK) currents in nerve growth factor-differentiated rat phaeochromocytoma (PC-12) cells and primary rat hippocampal neurones. Similar effects were exerted by Abeta(1-42), but not by the non-neurotoxic Abeta(35-25) peptide. Abeta(25-35) and Abeta(1-42) caused an early (15-20 min) increase in intracellular Ca(2+) concentration. This led to an increased production of reactive oxygen species (ROS), which peaked at 3 h and lasted for 24 h; ROS production seemed to trigger the VGK current increase as vitamin E (50 microm) blocked both the Abeta(25-35)- and Abeta(1-42)-induced ROS increase and VGK current enhancement. Inhibition of protein synthesis (cycloheximide, 1 microg/mL) and transcription (actinomycin D, 50 ng/mL) blocked Abeta(25-35)-induced VGK current enhancement, suggesting that this potentiation is mediated by transcriptional activation induced by ROS. Interestingly, the specific nuclear factor-kappaB inhibitor SN-50 (5 microm), but not its inactive analogue SN-50M (5 microm), fully counteracted Abeta(1-42)- or Abeta(25-35)-induced enhancement of VGK currents, providing evidence for a role of this family of transcription factors in regulating neuronal K+ channel function during exposure to Abeta.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • 4-Aminopyridine / pharmacology
  • Actin Cytoskeleton / metabolism
  • Amyloid beta-Peptides / chemistry
  • Amyloid beta-Peptides / toxicity*
  • Animals
  • Blotting, Western / methods
  • Calcium / metabolism
  • Cell Differentiation / drug effects
  • Cells, Cultured
  • Charybdotoxin / pharmacology
  • Chelating Agents / pharmacology
  • Cnidarian Venoms
  • Dactinomycin / pharmacology
  • Dose-Response Relationship, Drug
  • Drug Interactions
  • Egtazic Acid / pharmacology
  • Electric Stimulation / methods
  • Embryo, Mammalian
  • Enzyme Activation / drug effects
  • Enzyme Inhibitors / pharmacology
  • GAP-43 Protein / metabolism
  • Hippocampus / cytology*
  • Membrane Potentials / drug effects
  • Membrane Potentials / physiology
  • Membrane Potentials / radiation effects
  • NF-kappa B / metabolism*
  • Nerve Growth Factor / pharmacology
  • Neurons / drug effects*
  • Neurons / physiology
  • PC12 Cells / cytology
  • PC12 Cells / drug effects
  • Patch-Clamp Techniques / methods
  • Peptide Fragments / toxicity
  • Peptides / pharmacology
  • Potassium Channel Blockers / pharmacology
  • Potassium Channels, Voltage-Gated / physiology*
  • Protein Synthesis Inhibitors / pharmacology
  • Rats
  • Reactive Oxygen Species / metabolism*
  • Tetraethylammonium / pharmacology
  • Time Factors
  • Vitamin A / pharmacology

Substances

  • Amyloid beta-Peptides
  • BDS-I antiviral protein, Anemonia sulcata
  • Chelating Agents
  • Cnidarian Venoms
  • Enzyme Inhibitors
  • GAP-43 Protein
  • NF-kappa B
  • Peptide Fragments
  • Peptides
  • Potassium Channel Blockers
  • Potassium Channels, Voltage-Gated
  • Protein Synthesis Inhibitors
  • Reactive Oxygen Species
  • SN50 peptide
  • Vitamin A
  • Charybdotoxin
  • Dactinomycin
  • Egtazic Acid
  • Tetraethylammonium
  • Nerve Growth Factor
  • 4-Aminopyridine
  • Calcium